Despite demonstrating a significant survival advantage in the first-line treatment of unresectable hepatocellular carcinoma (HCC), the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) is ...

NovoCure (NVCR) stock rose 29% Thursday on early FDA approval for Optune Pax pancreatic cancer device, prompting H.C. Wainwright to raise target to $47.

The U.S. FDA has granted orphan drug designation to HCB101, an investigational immunotherapy, for the treatment of gastric cancer.

Radioligand therapies gained momentum in 2025 with FDA’s Pluvicto approval. Here’s why 2026 could drive growth and adoption.

A High Shincliffe youngster is set to undergo what his parents believe could be lifesaving treatment overseas after a huge fundraising drive ...

Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.

NovoCure NVCR shares are popping on Thursday following a major FDA approval that sent the stock soaring nearly 30% in ...

After customs duty cuts on 17 cancer drugs, India’s price regulator ordered MRPs revised to pass on benefits, but activists say tax relief alone won’t make costly patented therapies affordable.

In a new study that combines synthetic biology with cancer immunotherapy, researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Central ...

A Teesside couple are preparing to walk 50 miles between the North East’s three biggest football stadiums to raise money for a County Durham tot needing lifesaving cancer treatment overseas.

Katie Thurston’s stage 4 cancer diagnosis at age 34 felt like “the end of the world.” A year later, the former Bachelorette is planning a family — and raising awareness about breast cancer in young ...

Ibrutinib was a breakthrough when it was first approved to treat R/R MCL in 2013, and a year later for patients with at least 1 prior treatment for chronic lymphocytic leukemia. However, its ...